TRACTION accelerates translation of discoveries into new clinical approaches
Despite major recent advances in oncology drug discovery, including the development of innovative targeted, immune and cell-based therapies, there remain many opportunities to improve outcomes for patients with cancer. Some may not benefit from available treatments, and others may have highly aggressive or drug-resistant cancers that require new options.
As part of MD Anderson’s commitment to bring our patients the most effective...
Computer-assisted design technology complements navigation system in pioneering orthopaedic surgery
Combining a 3D virtual cutting guide with a surgical navigation tool allowed MD Anderson surgeons to perform a complicated pelvic reconstruction...
APOLLO’s high-quality longitudinal samples empower cancer investigators
Cancer’s ability to evolve in response to treatment and develop resistance to available therapies is one of the most significant challenges...
Multiple studies show major lack of public knowledge about HPV vaccine and cancer prevention
Despite the fact that the human papillomavirus (HPV) vaccine has been available in the U.S. for over 10 years and remains the only vaccine to protect against multiple types of cancer, several recent studies show that public knowledge about the vaccine and HPV’s relationship to cancer remains low.
HPV is responsible for 90% of cervical and anal cancers, and 70% of oropharyngeal (throat) cancers.
The first-generation HPV...
Moon Shot rises to challenge of glioblastoma
Glioblastoma (GBM) is not among the most commonly diagnosed cancers in the U.S., but it can certainly be among the most devastating. Of the...
Lung cancer targeted therapy hits common HER2 variants across cancers
Building upon the foundational discovery that the targeted therapy poziotinib is a potent and selective inhibitor of specific EGFR and HER2...